ES2478827T3 - Uso de inhibidores de histona desacetilasa para el tratamiento de síndromes mieloproliferativos Filadelfia negativos - Google Patents

Uso de inhibidores de histona desacetilasa para el tratamiento de síndromes mieloproliferativos Filadelfia negativos Download PDF

Info

Publication number
ES2478827T3
ES2478827T3 ES09783251.3T ES09783251T ES2478827T3 ES 2478827 T3 ES2478827 T3 ES 2478827T3 ES 09783251 T ES09783251 T ES 09783251T ES 2478827 T3 ES2478827 T3 ES 2478827T3
Authority
ES
Spain
Prior art keywords
phenylcarbamoyloxymethyl
hydroxycarbamoyl
naphthalen
diethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09783251.3T
Other languages
English (en)
Spanish (es)
Inventor
Tiziano Oldoni
Paolo Mascagni
Alessandro Rambaldi
Tiziano Barbui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Application granted granted Critical
Publication of ES2478827T3 publication Critical patent/ES2478827T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES09783251.3T 2008-09-29 2009-09-21 Uso de inhibidores de histona desacetilasa para el tratamiento de síndromes mieloproliferativos Filadelfia negativos Active ES2478827T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI2008A001720A IT1392908B1 (it) 2008-09-29 2008-09-29 Uso degli inibitori delle istone-deacetilasi per la cura di sindromi mieloproliferative philadelphia-negative
ITMI20081720 2008-09-29
US19328308P 2008-11-13 2008-11-13
US193283P 2008-11-13
PCT/EP2009/062214 WO2010034693A1 (en) 2008-09-29 2009-09-21 Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes

Publications (1)

Publication Number Publication Date
ES2478827T3 true ES2478827T3 (es) 2014-07-23

Family

ID=40810309

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09783251.3T Active ES2478827T3 (es) 2008-09-29 2009-09-21 Uso de inhibidores de histona desacetilasa para el tratamiento de síndromes mieloproliferativos Filadelfia negativos

Country Status (17)

Country Link
US (4) US20110294892A1 (https=)
EP (1) EP2344253B1 (https=)
JP (1) JP2012504112A (https=)
KR (3) KR20110069075A (https=)
CN (1) CN102164638A (https=)
BR (1) BRPI0913699A2 (https=)
CA (1) CA2738081C (https=)
CY (1) CY1115255T1 (https=)
DK (1) DK2344253T3 (https=)
ES (1) ES2478827T3 (https=)
HR (1) HRP20140499T1 (https=)
IT (1) IT1392908B1 (https=)
PL (1) PL2344253T3 (https=)
PT (1) PT2344253E (https=)
SI (1) SI2344253T1 (https=)
SM (1) SMT201400087B (https=)
WO (1) WO2010034693A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217079B2 (en) * 2010-03-26 2012-07-10 Italfarmaco Spa Method for treating Philadelphia-negative myeloproliferative syndromes
WO2015165975A1 (en) * 2014-04-29 2015-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating myeloid neoplasias
US20180127386A1 (en) 2016-10-20 2018-05-10 Forma Therapeutics, Inc. Methods using hdac11 inhibitors
US10865328B2 (en) * 2017-02-20 2020-12-15 Dow Silicones Corporation Room-temperature-curable silicone composition and electric/electronic apparatus
US11535607B2 (en) 2018-04-20 2022-12-27 Valo Health, Inc. Isoindolines as HDAC inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
ITMI20030063A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
ITMI20030064A1 (it) * 2003-01-17 2004-07-18 Italfarmaco Spa Uso dei derivati dell'acido idrossamico per la preparazione
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
WO2006063294A2 (en) * 2004-12-09 2006-06-15 Kalypsys, Inc. Novel inhibitors of histone deacetylase for the treatment of disease
CA2615574A1 (en) * 2005-07-29 2007-02-08 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
BRPI0619599A2 (pt) 2005-12-09 2011-10-11 Massachusetts Inst Technology método para inibir células de linhagem de tumor e para inibir o crescimento de tumores em um paciente
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
WO2008082646A2 (en) * 2006-12-28 2008-07-10 The Johns Hopkins University Histone deacetylase inhibitors, combination therapies and methods of use

Also Published As

Publication number Publication date
EP2344253A1 (en) 2011-07-20
EP2344253B1 (en) 2014-04-23
CY1115255T1 (el) 2017-01-04
KR20110069075A (ko) 2011-06-22
BRPI0913699A2 (pt) 2017-06-13
HRP20140499T1 (hr) 2014-07-04
PT2344253E (pt) 2014-07-16
CA2738081A1 (en) 2010-04-01
IT1392908B1 (it) 2012-04-02
PL2344253T3 (pl) 2014-09-30
WO2010034693A1 (en) 2010-04-01
SI2344253T1 (sl) 2014-08-29
DK2344253T3 (da) 2014-06-16
US20140039059A1 (en) 2014-02-06
US20170049740A1 (en) 2017-02-23
US20210128512A1 (en) 2021-05-06
ITMI20081720A1 (it) 2010-03-30
US9522127B2 (en) 2016-12-20
JP2012504112A (ja) 2012-02-16
SMT201400087B (it) 2014-09-08
KR20160096721A (ko) 2016-08-16
CN102164638A (zh) 2011-08-24
US20110294892A1 (en) 2011-12-01
CA2738081C (en) 2017-11-07
KR20170124640A (ko) 2017-11-10

Similar Documents

Publication Publication Date Title
US20210128512A1 (en) Use of histone deacetylase inhibitors for the care of philadelphia-negative myeloproliferative syndromes
ES2690061T3 (es) Composiciones para tratar la enfermedad de Parkinson
ES2534521T3 (es) Composiciones y su uso en el tratamiento de neoplasia, enfermedades inflamatorias y otras enfermedades
ES2496144T3 (es) Formulación de cápsulas de pirfenidona y excipientes farmacéuticamente aceptables
ES2665569T3 (es) Tratamiento de la isquemia cerebral
ES2690490T3 (es) Nuevas composiciones para tratar trastornos neurológicos
JP2005525345A (ja) Ｔｒｘ媒介性疾患を処置する方法
US20150038518A1 (en) Methods for the treatment of solid tumors
CN106470696A (zh) 用于治疗癌症的药物组合
ES2985012T3 (es) Administración conjunta de mirdametinib y lifirafenib para usar en el tratamiento del cáncer
JP2017519736A (ja) クラスｉｉｉ受容体チロシンキナーゼインヒビター及びアルキル化ヒストンデアセチラーゼインヒビター融合分子ｅｄｏ−ｓ１０１を含む医薬組合せ、並びに癌の処置におけるその使用
WO2007116396A1 (en) Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor
JP2016530317A (ja) 新規アントラニルアミドとその使用
KR101514320B1 (ko) 신규한 암 예방 또는 치료용 약학적 조성물
Himmerich et al. Mood stabilizers: Side effects, contraindications, and interactions
US8217079B2 (en) Method for treating Philadelphia-negative myeloproliferative syndromes
WO2022043955A1 (en) Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma
ES2972799T3 (es) Combinación farmacéutica de un compuesto de artemisinina, ácido 5-aminolevulínico o ácido metil-5-aminolevulínico y un agente quimioterapéutico
ES2309222T3 (es) Inhibidores no nucleosidos de la transcriptasa inversa como antagonistas de la proliferacion celular e inductores de la diferenciacion celular.
ES3028375T3 (en) 1,2-dihydroquinoline-2-ones for their use in the treatment of limb-girdle muscular dystrophy
ES2322148T3 (es) Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias.
Sánchez-Gayango et al. Amitriptilina serotoninérgica
KR20200055117A (ko) Pi3 키나아제 억제제 및 세포독성 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물
CA3119395C (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
ES2589169B1 (es) Uso de la pentoxifilina y de una composición farmacéutica para elaborar un medicamento para prevenir el envejecimiento prematuro en humanos